Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors.

Death receptors (DRs) can induce apoptosis by oligomerization with TRAIL, whereas death decoy receptors (DcRs) cannot, due to their lack of functional intracellular death domains. However, it is not known whether DRs and DcRs can interact with one another to form oligomeric complexes prior to TRAIL binding. To address this issue, the extracellular domains (ECDs) of DR4 (sDR4), DR5 (sDR5), DcR1 (sDcR1), and DcR2 (sDcR2) were expressed in a soluble, monomeric form, and their binding interactions were quantified by surface plasmon resonance. The purified sDRs and sDcRs exhibited native-like secondary structure and bound to TRAIL with binding affinities in the nanomolar range (K(D)= approximately 10-62 nM), suggesting that they were properly folded and functional. The soluble receptors interacted homophilically and heterophilically with similar micromolar range affinities (K(D)= approximately 1-9 microM), with the exception that sDR5 did not interact with the sDcRs. Our results suggest that most DRs and DcRs can laterally interact through their ECDs to form homomeric and/or heteromeric complexes in the absence of TRAIL binding.

[1]  Pei-shan Wu,et al.  Biochemical and Biophysical Research Communications , 1960, Nature.

[2]  M. S. Lee,et al.  Crystal Structure of TRAIL-DR5 Complex Identifies a Critical Role of the Unique Frame Insertion in Conferring Recognition Specificity* , 2000, The Journal of Biological Chemistry.

[3]  R M Siegel,et al.  A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. , 2000, Science.

[4]  P. Hersey,et al.  Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. , 2001, Cancer research.

[5]  J. Blenis,et al.  Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8* , 2001, The Journal of Biological Chemistry.

[6]  A. Ashkenazi,et al.  Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.

[7]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[8]  S R Sprang,et al.  Crystallographic Evidence for Dimerization of Unliganded Tumor Necrosis Factor Receptor (*) , 1995, The Journal of Biological Chemistry.

[9]  A. Ashkenazi,et al.  Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. , 2003, Cytokine & growth factor reviews.

[10]  W I Wood,et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.

[11]  Emad S. Alnemri,et al.  Temperature-sensitive Differential Affinity of TRAIL for Its Receptors , 2000, The Journal of Biological Chemistry.

[12]  C. Smith,et al.  Functional analysis of TRAIL receptors using monoclonal antibodies. , 1999, Journal of immunology.

[13]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[14]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[15]  D. Lawrence,et al.  Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. , 2000, Immunity.

[16]  B. Oh,et al.  2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. , 1999, Immunity.

[17]  M. Ultsch,et al.  Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. , 1999, Molecular cell.

[18]  J K Frederiksen,et al.  Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. , 2000, Science.

[19]  N. Sreerama,et al.  Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. , 2000, Analytical biochemistry.

[20]  D. Seol,et al.  Cysteine 230 modulates tumor necrosis factor-related apoptosis-inducing ligand activity. , 2000, Cancer research.

[21]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[22]  M. Ultsch,et al.  A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. , 2000, Biochemistry.

[23]  D. Stuart,et al.  Structure of the TRAIL–DR5 complex reveals mechanisms conferring specificity in apoptotic initiation , 1999, Nature Structural Biology.

[24]  P. Hersey,et al.  Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. , 1999, Cancer research.

[25]  R. Gentz,et al.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.

[26]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[27]  Y. Jang,et al.  Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities. , 2003, Cancer letters.

[28]  I. Wilson,et al.  Erythropoietin receptor activation by a ligand-induced conformation change. , 1999, Science.

[29]  P. Schneider,et al.  Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. , 2000, Methods in enzymology.

[30]  Karen Billeci,et al.  Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling* , 2005, Journal of Biological Chemistry.

[31]  Gongyi Zhang.  Tumor necrosis factor family ligand-receptor binding. , 2004, Current opinion in structural biology.

[32]  V. Dixit,et al.  TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling , 1998, FEBS letters.